Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02540122 · ClinicalTrials.gov registry record · Phase 1
Pilot Clinical Evaluation of Approved Contact Lenses
A Phase 1 study, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02540122: Completed Phase 1 study, sponsored by Johnson & Johnson Vision Care.
NCT02540122 is a Phase 1 study that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02540122, a Phase 1 study, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a pilot evaluation to assess the feasibility of using novel imaging process to characterize lens edge and limbal epithelial thickness profile; lens movement with gaze and blink; and conjunctival microvasculature including fractal analysis of microvascular perfusion maps and blood flow velocity.
Primary Outcome
Bulbar conjunctival microvascular responses among different types of contact lenses after a period of lens wear will be observed and evaluated for clinical relevance findings.
Interventions
- DEVICE Marketed Contact Lens 1
- DEVICE Marketed Contact Lens 2
- DEVICE Marketed Contact Lens 3
- DEVICE Marketed Contact Lens 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
What the finished NCT02540122 record still lists
NCT02540122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 4 interventions - of which Marketed Contact Lens 1 is the first listed.
NCT02540122 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02540122 about?
NCT02540122 is a clinical study titled "Pilot Clinical Evaluation of Approved Contact Lenses". This is a pilot evaluation to assess the feasibility of using novel imaging process to characterize lens edge and limbal epithelial thickness profile; lens movement with gaze and blink; and conjunctival microvasculature including fractal analysis of microvascular perfusion maps and blood flow veloci...
What is the current status of trial NCT02540122?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-08. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02540122?
The interventions under investigation include: Marketed Contact Lens 1 (DEVICE), Marketed Contact Lens 2 (DEVICE), Marketed Contact Lens 3 (DEVICE), Marketed Contact Lens 4 (DEVICE).
Who is sponsoring clinical trial NCT02540122?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02540122's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia